Basic Information
| LncRNA/CircRNA Name | MYMLR |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung adenocarcinoma |
| ICD-0-3 | C34 |
| Methods | Microarray, qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, RIP |
| Sample | The A549 lung adenocarcinoma cell line, the ACC-LC-319 lung adenocarcinoma cell line, normal and tumor tissues |
| Expression Pattern | differential expression |
| Function Description | MYMLR was identified and experimentally shown to maintain MYC transcriptional activity and cell cycle progression despite the low levels of expression. A proteomic search for MYMLRbinding proteins identified PCBP2, while it was also found that MYMLR places a 557-kb upstream enhancer region in the proximity of the MYC promoter in cooperation with PCBP2. |
| Pubmed ID | 31361039 |
| Year | 2019 |
| Title | Divergent lncRNA MYMLR regulates MYC by eliciting DNA looping and promoter-enhancer interaction |
External Links
| Links for MYMLR | GenBank HGNC NONCODE |
| Links for lung adenocarcinoma | OMIM COSMIC |